

## 18 March 2025 | News

### Australia serves as a launchpad for broader commercialisation, with the US to follow



PromarkerD is a clinically validated blood test that can predict the risk of developing chronic kidney disease (DKD) in type 2 diabetes patients up to four years before clinical symptoms appear. This early warning provides healthcare professionals with a critical window to intervene, enabling better patient management and reducing the risk of severe kidney complications, including kidney failure and the need for dialysis or transplant.

The commercial launch of PromarkerD into its home market is a key milestone in Proteomics International's global commercialisation strategy. Having built a fully integrated digital solution for direct-to-consumer engagement the Company is now well-positioned to support the early detection of diabetic kidney disease for Australian patients.

PromarkerD will initially be available through referral by a healthcare professional in Western Australia and the Northern Territory, before the test is made available nationwide.

The company will now collaborate with health insurers, patient advocacy groups, and government bodies to explore potential reimbursement pathways, aiming to make the test (priced at AUS \$245) accessible to all Australians living with diabetes.